

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human OCIL/CLEC2d in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant mouse (rm) OCIL is observed and less than 1% cross-reactivity with recombinant human (rh) CLEC2B, and rhCLEC2A i
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	<i>E. coli</i> -derived recombinant human OCIL/CLEC2d Ser57-Val191 Accession # Q9UHP7
Conjugate	Alexa Fluor 532 Excitation Wavelength: 534 nm Emission Wavelength: 553 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

CyTOF-ready	Optimal dilution of this antibody should be experimentally determined.
Western Blot	Optimal dilution of this antibody should be experimentally determined.
Flow Cytometry	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Human OCIL/CLEC2d, also known as Lectin-Like Transcript-1 (LLT-1), is a type II transmembrane protein belonging to the natural killer (NK) cell receptor group of the C-type lectin superfamily. It is found on hematopoietic cells, osteoblasts, and chondrocytes. By alternative splicing, at least three isoforms exist. Isoform 1 is synthesized as a 191 amino acid (aa) precursor with a C-terminal 132 aa extracellular domain (ECD) that contains the C-type lectin domain. The aa sequence of human OCIL isoform 1 ECD is 49% and 50% identical to the mouse and rat OCIL ECD, respectively. Human OCIL preferentially binds high molecular weight sulfated glycosaminoglycans and is a ligand for the single human NKR-P1A receptor (CD161). Human OCIL blocks osteoclast differentiation. Engagement of OCIL with CD161 on NK cells also inhibits NK cell-mediated cytotoxicity and IFN-γ secretion.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.